Cargando…

Progress in the Therapeutic Applications of siRNAs Against HIV-1

Therapeutic options against the human immunodeficiency virus type 1 (HIV-1) continue to expand with the development of new drugs and new therapeutic strategies. Nevertheless, management of HIV-1 infected individuals has become increasingly complex. The emergence of drug-resistant variants, the growi...

Descripción completa

Detalles Bibliográficos
Autor principal: Martínez, Miguel Angel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121013/
https://www.ncbi.nlm.nih.gov/pubmed/19301656
http://dx.doi.org/10.1007/978-1-60327-547-7_17
_version_ 1783515104781795328
author Martínez, Miguel Angel
author_facet Martínez, Miguel Angel
author_sort Martínez, Miguel Angel
collection PubMed
description Therapeutic options against the human immunodeficiency virus type 1 (HIV-1) continue to expand with the development of new drugs and new therapeutic strategies. Nevertheless, management of HIV-1 infected individuals has become increasingly complex. The emergence of drug-resistant variants, the growing recognition of the long-term toxicity of antiretroviral therapies and the persistence of viral reservoirs justify the continued efforts to develop new anti-HIV-1 strategies. Recent advances regarding the utility of RNA-mediated interference (RNAi) to specifically inhibit HIV-1 replication have opened new possibilities for the development of gene-based therapies against HIV-1 infection. Here, the recent advances in siRNA-based therapies are reviewed.
format Online
Article
Text
id pubmed-7121013
institution National Center for Biotechnology Information
language English
publishDate 2008
record_format MEDLINE/PubMed
spelling pubmed-71210132020-04-06 Progress in the Therapeutic Applications of siRNAs Against HIV-1 Martínez, Miguel Angel siRNA and miRNA Gene Silencing Article Therapeutic options against the human immunodeficiency virus type 1 (HIV-1) continue to expand with the development of new drugs and new therapeutic strategies. Nevertheless, management of HIV-1 infected individuals has become increasingly complex. The emergence of drug-resistant variants, the growing recognition of the long-term toxicity of antiretroviral therapies and the persistence of viral reservoirs justify the continued efforts to develop new anti-HIV-1 strategies. Recent advances regarding the utility of RNA-mediated interference (RNAi) to specifically inhibit HIV-1 replication have opened new possibilities for the development of gene-based therapies against HIV-1 infection. Here, the recent advances in siRNA-based therapies are reviewed. 2008-10-13 /pmc/articles/PMC7121013/ /pubmed/19301656 http://dx.doi.org/10.1007/978-1-60327-547-7_17 Text en © Humana Press, a part of Springer Science+Business Media, LLC 2009 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Martínez, Miguel Angel
Progress in the Therapeutic Applications of siRNAs Against HIV-1
title Progress in the Therapeutic Applications of siRNAs Against HIV-1
title_full Progress in the Therapeutic Applications of siRNAs Against HIV-1
title_fullStr Progress in the Therapeutic Applications of siRNAs Against HIV-1
title_full_unstemmed Progress in the Therapeutic Applications of siRNAs Against HIV-1
title_short Progress in the Therapeutic Applications of siRNAs Against HIV-1
title_sort progress in the therapeutic applications of sirnas against hiv-1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121013/
https://www.ncbi.nlm.nih.gov/pubmed/19301656
http://dx.doi.org/10.1007/978-1-60327-547-7_17
work_keys_str_mv AT martinezmiguelangel progressinthetherapeuticapplicationsofsirnasagainsthiv1